全文获取类型
收费全文 | 14747篇 |
免费 | 3216篇 |
国内免费 | 350篇 |
专业分类
耳鼻咽喉 | 283篇 |
儿科学 | 271篇 |
妇产科学 | 301篇 |
基础医学 | 1243篇 |
口腔科学 | 134篇 |
临床医学 | 2058篇 |
内科学 | 3321篇 |
皮肤病学 | 602篇 |
神经病学 | 1098篇 |
特种医学 | 495篇 |
外科学 | 3111篇 |
综合类 | 963篇 |
预防医学 | 990篇 |
眼科学 | 730篇 |
药学 | 1087篇 |
1篇 | |
中国医学 | 396篇 |
肿瘤学 | 1229篇 |
出版年
2024年 | 107篇 |
2023年 | 808篇 |
2022年 | 370篇 |
2021年 | 669篇 |
2020年 | 619篇 |
2019年 | 425篇 |
2018年 | 922篇 |
2017年 | 971篇 |
2016年 | 908篇 |
2015年 | 1001篇 |
2014年 | 1249篇 |
2013年 | 1175篇 |
2012年 | 1028篇 |
2011年 | 962篇 |
2010年 | 898篇 |
2009年 | 964篇 |
2008年 | 678篇 |
2007年 | 586篇 |
2006年 | 603篇 |
2005年 | 510篇 |
2004年 | 364篇 |
2003年 | 330篇 |
2002年 | 266篇 |
2001年 | 242篇 |
2000年 | 198篇 |
1999年 | 207篇 |
1998年 | 168篇 |
1997年 | 170篇 |
1996年 | 123篇 |
1995年 | 133篇 |
1994年 | 91篇 |
1993年 | 60篇 |
1992年 | 72篇 |
1991年 | 75篇 |
1990年 | 51篇 |
1989年 | 56篇 |
1988年 | 45篇 |
1987年 | 30篇 |
1986年 | 33篇 |
1985年 | 13篇 |
1984年 | 14篇 |
1983年 | 15篇 |
1982年 | 16篇 |
1981年 | 15篇 |
1980年 | 9篇 |
1979年 | 8篇 |
1977年 | 6篇 |
1973年 | 5篇 |
1971年 | 7篇 |
1969年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 2 毫秒
1.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
2.
3.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study
下载免费PDF全文
![点击此处可从《Journal of clinical nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
4.
5.
Evaluation of training nurses to perform semi‐automated three‐dimensional left ventricular ejection fraction using a customised workstation‐based training protocol
下载免费PDF全文
![点击此处可从《Journal of clinical nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
6.
7.
Phytonutrients extracted from natural resources are receiving much attention among researchers due to their highly antioxidative characteristics which prevent several degenerative diseases including cardiovascular diseases and cancers. These nutraceutical compounds can be used in food, pharmaceutical and cosmetic products as natural antioxidants, preservatives, colourants and functional foods. Huge volume of food wastes are generated from the processing industry and these low-value food residues are rich in various phytonutrients worth recovering. This approach of valorisation reduces the generation of food wastes and is cost-effective considering the cheap feedstock, reduced waste management expenses and high market value of extracted compounds. In light of the health and safety risks posed by commonly used organic extraction solvents derived from the petrochemical industry, there is a need to recover the phytonutrients using green, sustainable and efficient solvents that are safe for human consumption. This work discusses ethyl lactate as a safe, green, efficient and potentially cheap solvent to recover phytonutrients from fruit and vegetable by-products. Ethyl lactate is compared with other organic solvents commonly used from the aspects of safety, environmental impacts and efficiency. Current challenges when employing ethyl lactate are also discussed. 相似文献
8.
9.
10.
Gregory N. Gan 《Expert opinion on investigational drugs》2016,25(10):1153-1166
Introduction: Cancer treatment is moving away from conventional cytotoxic drugs and towards agents that target specific proteins and mechanisms important to cancer development or survival. The Hedgehog Pathway (HhP) is a signal transduction pathway and its constitutive activation is tumorigenic in basal cell carcinoma (BCC). The HhP enables phenotypic flexibility, and channels tumor-stroma interactions. As a result, it is over-expressed in numerous cancers as well as in the tumor microenvironment and may represent a promising therapeutic target.Areas covered: In this article, we review the rationale for targeting HhP and its role as an oncogenic driver, in tumor epithelial-to-mesenchymal transition (EMT), and in the tumor microenvironment and describe the results of preclinical and clinical studies involving HhP inhibitors.Expert opinion: HhP activation plays an important role in both the tumor microenvironment and tumor EMT which can lead to treatment resistance for a number of different malignancies. In addition to standard use in BCC, several HhP inhibitors are in preclinical, early, and mid-stage clinical development for other solid and hematologic malignancies. 相似文献